However, a previous phase II study of gefitinib as a second-line treatment for advanced esophageal cancer reported a significantly higher disease control rate (response and SD) in patients with ESCC expressing high levels of EGFR. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.